Pharmacokinetics of linagliptin in subjects with hepatic impairment

The DPP-4 inhibitor linagliptin does not prolong the QT interval at therapeutic and supratherapeutic doses

(2011) Arne Ring et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Nonalcoholic fatty liver disease in type 2 diabetes mellitus

(2011) Kenneth Cusi   Current Opinion in Endocrinology Diabetes and Obesity

Pharmacokinetics and Pharmacodynamics of Single Rising Intravenous Doses (0.5 mg–10 mg) and Determination of Absolute Bioavailability of the Dipeptidyl Peptidase-4 Inhibitor Linagliptin (BI 1356) in Healthy Male Subjects

(2010) Silke Retlich et al.   CLINICAL PHARMACOKINETICS

Pharmacokinetics of dipeptidylpeptidase-4 inhibitors

(2010) A. J. Scheen   DIABETES OBESITY & METABOLISM

Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study

(2010) M.-R. Taskinen et al.   DIABETES OBESITY & METABOLISM

Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial

(2010) S. Del Prato et al.   DIABETES OBESITY & METABOLISM

The changing pattern of epidemiology in hepatocellular carcinoma

(2010) Helena Nordenstedt et al.   DIGESTIVE AND LIVER DISEASE

The Metabolism and Disposition of the Oral Dipeptidyl Peptidase-4 Inhibitor, Linagliptin, in Humans

(2010) S. Blech et al.   DRUG METABOLISM AND DISPOSITION

Impact of Target-Mediated Drug Disposition on Linagliptin Pharmacokinetics and DPP-4 Inhibition in Type 2 Diabetic Patients

(2010) Silke Retlich et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Tissue distribution of the novel DPP-4 inhibitor BI 1356 is dominated by saturable binding to its target in rats

(2009) Holger Fuchs et al.   BIOPHARMACEUTICS & DRUG DISPOSITION

Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients

(2009) T. Heise et al.   DIABETES OBESITY & METABOLISM

Altered functions and expressions of drug transporters in liver, kidney and intestine in disorders of local and remote organs: possible role of oxidative stress in the pathogenesis

(2009) Kenji Ikemura et al.   Expert Opinion on Drug Metabolism & Toxicology

Concentration-dependent plasma protein binding of the novel dipeptidyl peptidase 4 inhibitor BI 1356 due to saturable binding to its target in plasma of mice, rats and humans

(2009) Holger Fuchs et al.   JOURNAL OF PHARMACY AND PHARMACOLOGY

Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors

(2009) Joshua J. Neumiller   JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION

Liver cirrhosis and diabetes: Risk factors, pathophysiology, clinical implications and management

(2009) Diego Garcia-Compean et al.   WORLD JOURNAL OF GASTROENTEROLOGY

QT interval prolongation and decreased heart rate variability in cirrhotic patients: relevance of hepatic venous pressure gradient and serum calcium

(2008) Simonetta Genovesi et al.   CLINICAL SCIENCE

Influence of fruit juices on drug disposition: discrepancies betweenin vitroand clinical studies

(2008) Dora Farkas et al.   Expert Opinion on Drug Metabolism & Toxicology

(R)-8-(3-Amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a Novel Xanthine-Based Dipeptidyl Peptidase 4 Inhibitor, Has a Superior Potency and Longer Duration of Action Compared with Other Dipeptidyl Peptidase-4 Inhibitors

(2008) L. Thomas et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS